BTK Inhibitors for the First-Line Treatment of CLL

Описание: In this video capsule, Dr. Laurie Sehn leads a discussion with Dr. Jennifer Brown on the topic of BTK inhibitors for the treatment of first-line chronic lymphocytic leukemia

Our Guests:
Dr. Laurie Sehn is a Clinical Assistant Professor in the Department of Medicine at the University of British Columbia. She has been a medical oncologist and clinical investigator at the BC Cancer Agency since 1998 and is currently the Chair of the Lymphoma Tumour Group. Dr. Sehn is Chair of the medical advisory board for the International Lymphoma Coalition and also serves as co-chair of the Lymphoma Site of the Canadian Cancer Trials Group.

Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute (DFCI) and the Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts, where she has an active clinical-translational research program in CLL. Her interests include the development of novel targeted therapeutics for CLL, as well as CLL genomics. She has published about 335 papers in the scientific literature, predominantly in CLL.

This video capsule was sponsored by BeiGene Canada ULC

If you enjoyed this video, please like and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com/